- Email: [email protected]
Index to Volume 5
NEURODEGENERATION
Index to Volume 5 Author Index Agid, Y. 121 Alessandrì, M.G. 241 Altomare, C. 265 Anglade, P. 121 Araujo, D.M. 197 Armstrong, R.A. 35 Asami-Odaka, A. 13 Bailey, S.J. 319 Baker, H.F. 219, 467 Bakker, R. 153 Barton, A.J.L. 213, 293 Bassi, L. 241 Baxter, H.C. 1 Benjamin, R. 43 Bennett, J.P. Jr 233 Bettendorf, L. 27 Bjertness, E. 43 Boccardi, B. 351 Bogdanovich, N. 169 Bongioanni, P. 351 Borgna, M. 351 Brady, D.R. 473 Bratosiewicz, J. 95 Bresciani, L.G. 293 Brown, F. 213 Brown, P. 95 Brown, R.H. Jr 57 Bruce, M.E. 101 Cairns, N.J. 35 Caivano, M. 293 Campbell, C.A. 319 Candy, J.M. 43 Carotti, A. 265 Carrupt, P-A. 265 Cartwright, H. 177 Cartwright, H.R. 49 Castagna, M. 351 Cavalletti, M. 129 Cellamare, S. 265 Chandrasekaran, K. 473 Chessell, I.P. 453 Chong, A. 1 Clark, R.F. 213 Clowry, G.J. 65 Cohen, D.L. 497 Collins, F. 197 Collins, P. 145 Corsini, G.U. 129, 241 Cowburn, R.F. 19, 169, 483 Cramer, H. 359 Crook, B.W. 213 Crook, R. 207 Cross, A.J. 81 Croxton, R. 207 Cullen, K.M. 177 Cutler, N.R. 511 Czl-onkowska, A. 137 Czl-onkowski, A. 137 Davis, J.B. 293, 441 DeKosky, S.T. 417 Dewar, D. 213 Donaldson, D.M. 57
Douma, B.R.K. 153 Duff, K. 213, 293 Edwardson, J.A. 43 Efthimiopoulos, S. 445 Fascetti, F. 129 Fornai, F. 129, 241 Fowler, C.J. 483 Fowler, N. 101 Fox, N.C. 393 Francis, P.T. 461 Freeborough, P.A. 393 Fukumoto, H. 13 Gajdusek, D.C. 95 Garlind, A. 169 Garruto, R.M. 325 German, D.C. 299, 313 Goate, A.M. 213 Goodsir, C.M. 101 Graham, D.I. 213 Grauer, M.T. 359 Gray, C.W. 293 Green, A.R. 81 Halliday, G.M. 49, 177 Haltia, T. 207 Hamann, G.F. 359 Hamilton, T.C. 319 Harder, J.A. 467 Hardman, C.D. 49 Hardy, J. 207, 213, 293 Harrison, P.J. 409 Harvey, R.J. 393 Hatanpää, K. 473 Haug, L.S. 169 He, B.P. 73 Heffernan, J.M. 409 Hilt, D. 197 Hindmarsh, J.G. 145 Hironishi, M. 325 Hirsch, E.C. 121 Hirsch, O. 57 Hope, J. 1, 101 Hope, T. 399 Hunt, S. 145 Hutton, M. 207, 213, 293 Ince, P.G. 43 Ironside, J.W. 87 Iwatsubo, T. 13, 115 Jackson, M. 339 Jeffrey, M. 101 Jen, A. 489 Jenner, P 145, 265 Jiao, S. 197 Jung, A.B. 233 Kalaria, R.N. 497 Karran, E.H. 207, 213, 293 Keene, J. 399 Kelly, S.M. 1 Kilborn, J.R. 511 King, P.D. 319 Kish, S.J. 27 Kloszewska, I. 95
Kohutnicka, M. 137 Kordek, R. 95, 325 Kril, J.J. 177 Kurkowska-Jastrze,bska, I.
137
Lakshmana, M.K. 161 LaMarche, J. 27 Lancaster, S. 207 Lange, D. 57 Lantos, P.L. 35 Lapchak, P.A. 197 Leake, A. 43 Lennox, G. 339 Leong, S.K. 73 Liang, C-L. 299, 313 Liberski, P.P. 95 Lindsay, G. 27 Lowe, J. 339 Luiten, P.G.M. 153 McArthur, F.K. 43 McBride, P.A. 101 MacDonald, S.T. 87 Mackay, K.B. 319 McKenna-Yasek, D. 57 McKenzie, J.E. 251, 259 McNaught, K.St.P. 265 McRitchie, D.A. 49 Makino, M. 287 Mann, D.M.A. 115, 213, 423 Marsden, C.D. 265 Marshall, J.W.B. 275 Mastrogiacomo, F. 27 Miller P.J. 197 Miura, S. 331 Mondino, C. 351 Morris, C.M. 43 Morris, J.G.L. 49 Mouatt-Prigent, Annick 121 Munirathinam, S. 161 Murphy, P.L. 57 Murphy, V.F. 293 Myers, D. 35 Naini, A.B. 57 Nelson, E.L. 299 Nitsch, R.M. 477 Nyakas, C. 153 Ohnuki, Y. 331 Ohtani, Y. 331 Okada, Y. 287 O’Neill, C. 483 Østwald, A.C. 169 Palmer, A.M. 381 Pangalos, M.N. 445 Patel, A.J. 491 Patel, S. 319 Pearson, R.C.A. 213, 409, 429 Perez-Tur, J. 207 Phillips, H. 207 Premkumar, D.R.D. 497 Price, N.C. 1 Procter, A.W. 399 Przedborski, S. 57 Raju, T.R.
161
Rapoport, S.I. 473 Ravid, R. 19 Ridley, R.M. 219, 275, 467 Robakis, N.K. 445 Roberts, G.W. 207, 213, 251, 259, 293 Robitaille, Y. 27 Rohan de Silva, H.A. 489 Rose, S. 145 Rossor, M.N. 35, 393 Royston, M.C. 251, 259 Sanders, M.W. 409 Sato, A. 287 Scalori, V. 241 Scheff, S.W. 417 Schimrigk, K. 359 Schut, L. 27 Sen, P. 65 Shearman, M.S. 1 Shioi, J. 445 Sims, N.R. 435 Sinton, C.M. 299, 313 Smith, C.U.M. 35 Smith, T.S. 233 Sonsalla, P.K. 299, 313 Speciale, S.G. 299 Sramek, J.J. 511 Strittmatter, M. 359 Stuiver, B.T. 153 Styren, S.D. 417 Sutherland, K. 87 Suzuki, N. 13 Sydserff, S.G. 81 Tabira, T. 287 Tamai, Y. 331 Tan, C.K. 367 Tanaka, M. 287 Tay, S.S.W. 73 Tedeschi, D. 129 Testa, B. 265 Thull, U. 265 Torracca, M.T. 241 Torvik, A. 43 Trimmer, P.A. 233 Vaglini, F. 129 Vrbová, G. 65 Walaas, S.I. 169 Ward, R.V. 293 Wickenden, C. 489 Wiehager, B. 19 Wighton-Benn, W.H. 409 Wilcock, G.K. 505 Winblad, B. 19, 169 Wong, W.C. 367 Wright, K. 207 Wu, A. 445 Yanagihara, R. 95, 325 Zehr, C. 207 Zhang, Y.L. 367
ii Subject Index Acetylcholine Alzheimer’s disease neurochemical pathology 403, 461, 477, 489 hippocampus neurochemical modulation 467 muscarinic receptors: Alzheimer’s disease changes 19 pyramidal neurones modulation for Alzheimer’s treatments 461 Actinomycin D, RNA synthesis inhibition/neurone survival 65 Adenylyl cyclase, signal transduction 483 AIDS, LP-BM5 murine leukaemia virus infection of brain capillary endothelial cells 287 Aluminium, (-)deprenyl protection 161 Alz-50, neurofibrillary damage 251, 259 Alzheimer’s disease (-)deprenyl protection against aluminium 161 Aβ40 and microglia 13 acetylcholine muscarinic receptor changes 19 acetylcholine receptor targets on cortical pyramidal neurones 453 amyloid β (Aβ) protein deposition 35 apolipoprotein E 43 appican characterization 445 beta amyloid protein stain techniques 177 calcium homeostasis 169 cognitive function 473 cortical connections 429 dementia: biochemistry/clinical aspects 399 energy metabolism 435, 473 familial, sporadic 393 glial cell-derived neurotrophic factors 489 inflammatory response: cellular aspects 497 monoamine oxidase molecular activity 351 neurofibrillary tangles image analysis 251, 259 neuronal degeneration 435 neurotransmitters 381, 403, 477, 483 oxidative phosphorylation down-regulation 473 oxidative stress 435 presenilin 1, 207, 213, 293 prion protein peptide cytotoxicity 1 pyramidal neurones 423, 461 signal transduction 393 somatostatin 359 sporadic 35, 393 synapse change 417 treatments 505, 511 Amyloid protein Alzheimer’s disease/Down’s syndrome comparison 35 Down’s syndrome 35, 115 genesis 491 immuno-localisation of synthetic prion protein peptide antibodies in 87V murine scrapie 101 microwave processing of formalin-fixed tissue sections 95 senile plaques 13 stain techniques 177 Amyotrophic lateral sclerosis blood free radical scavenging enzymes 57 inclusion dementia 339 neurofibrillary lesions quantification 251 Antigen presenting cells, LP-BM5 murine leukaemia virus infection of brain capillary endothelial cells 287 Apo E see apolipoprotein E Apolipoprotein E (Apo E), Alzheimer’s disease 43 Apoptosis maltol neurotoxicology 325 RNA synthesis inhibition/neurone survival after injury at birth (rat) 65 Appican, characterization 445 Automated image analysis, neurofibrillary tangles in Alzheimer’s disease 251
Axotomies ciliary ganglionic ultrastructure following preganglionic axotomy 367 RNA synthesis inhibition/neurone survival 65 Behavioural problems, dementia: biochemistry/clinical aspects 399 Beta amyloid precursor protein appican characterization 445 cytotoxicity mechanism of prion protein peptide 1 inflammatory response cellular aspects 499 mRNAs 409 neurotrophic factors 489 signal transduction 483 Beta amyloid protein, cytotoxicity oxidative mechanisms 441 Binswanger’s disease, somatostatin 359 Blood, free radical scavenging enzymes in amyotrophic lateral sclerosis 57 Bovine spongiform encephalopathy (BSE), strain variation 226 Bowen, Professor David M.: tribute 379 Brain capillary endothelial cells, LP-BM5 murine leukaemia virus infection 287 Bridging treatments 513 C57BL/6J mice, common peroneal nerve lesion, macrophage/ microglial cell reaction 73 Calbindin-D28k, MPTP-induced degeneration of midbrain dopaminergic neurons 313 Calcium antagonists neuroprotection against NMDA-induced excitotoxicity 153 homoeostasis in Alzheimer’s disease 169 parvalbumin-containing neurons in substantia nigra pars reticulata in Parkinson’s disease 49 Calpain, Alzheimer’s disease 169 Capillary endothelial cells, LP-BM5 murine leukaemia virus infection 287 Catalase, amyotrophic lateral sclerosis 57 Cats, ciliary ganglionic ultrastructure following preganglionic axotomy 367 Caudate nucleus, Parkinson’s disease synaptic plasticity 121 Cells death see Apoptosis inflammatory response in Alzheimer’s disease 497 receptor targets for Alzheimer’s treatments 453 Cerebellum Down’s syndrome amyloid protein analysis 115 α-ketoglutarate dehydrogenase complex levels in Friedrich’s ataxia/spinocerebellar ataxia type 1 27 Cerebral cortex (-) deprenyl neuroprotection 161 Alzheimer’s disease pathways of spread 429 dexfenfluramine neurotoxicity in rats 145 IP3 receptors in Alzheimer’s disease 169 neurofibrillary tangles automated image analysis 251 pyramidal neurones: acetylcholine receptor targets cellular localization for Alzheimer’s therapies 453 Cerebrospinal fluid, somatostatin-like immunoreactivity in Binswanger’s disease 359 Chlormethiazole, oedema in middle cerebral artery-occluded rat brain 81 N-(-2-Chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4), monoamine depletion patterns in rodents 241 Cholinergic factors Alzheimer’s disease neurochemical pathology 403, 461, 477, 489 amyloidogenesis in Alzheimer’s disease 489 hippocampus neurochemical modulation 467 muscarinic receptors: Alzheimer’s disease changes 19
iii pyramidal neurones modulation for Alzheimer’s treatments 461 Chondroitin sulfate, appican characterization 445 Ciliary ganglia, ultrastructure following preganglionic axotomy 367 Circular dichroism, prion protein peptide cytotoxicity 1 [3H]citalopram binding, dexfenfluramine neurotoxicity in rat cortex 145 CJD see Creutzfeld-Jakob disease Clinical features Alzheimer’s disease: sporadic familial 393 Alzheimer’s disease bridging treatments 513 dementia behavioural problems 399 Cognitive function, Alzheimer’s disease 417, 473 Combined therapies, nimodipine/MK-801 153 Common peroneal nerve, macrophage/microglial cell reaction after cut and crush 73 Computer-imaging, MPTP-induced degeneration of midbrain dopaminergic neurons 299 Connections, cortical in Alzheimer’s disease 429 Cortex (-) deprenyl neuroprotection 161 connections/pathways in Alzheimer’s disease 429 dexfenfluramine neurotoxicity in rats 145 IP3 receptors in Alzheimer’s disease 169 neurofibrillary tangles automated image analysis 251 pyramidal neurones: acetylcholine receptor targets cellular localization for Alzheimer’s therapies 453 Creutzfeld-Jakob disease (CJD) ganglioside alterations in central/peripheral nervous system 331 prion protein immunohistochemistry 87 strain variation evidence for independent genome 219 Cytokines, plaque-associated 489 Cytotoxic T cells, LP-BM5 murine leukaemia virus infection of brain capillary endothelial cells 287 Cytotoxicity, prion protein peptide 1 Degeneration, ciliary ganglionic ultrastructure following preganglionic axotomy 367 Dementia Alzheimer’s disease beta amyloid precursor protein mRNAs 409 neurochemical studies 381, 403, 477, 483 structural correlates of cognition 417 behavioural problems: biochemistry/clinical aspects 399 monoamine oxidase molecular activity 351 motor neurone disease 339 pugilistica: neurofibrillary damage analysis 259 somatostatin-like immunoreactivity 359 Dendritic spines, Parkinson’s disease synaptic plasticity 121 (-) Deprenyl neuroprotection against aluminium 161 striatal MPP+ levels after MPTP treatment 129 Dexfenfluramine, neurotoxicity in rat cortex 145 Diffuse plaques, Down’s syndrome amyloid protein analysis 115 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide see MTT Dopaminergic neurons microglial reaction in MPTP-induced Parkinson’s 137 MPP+/MPTP neurotoxicity 129 MPTP neurotoxicity resistance in p53 gene knockout mice 233 MPTP-induced midbrain degeneration 299, 313 Double-labelling immunocytochemistry, MPTP-induced degeneration of midbrain dopaminergic neurons 313 Down’s syndrome amyloid protein 35, 115 neurofibrillary damage 259
DSP-4 see N-(-2-Chloroethyl)-N-ethyl-2-bromobenzylamine Elderly brains, amyloid β (Aβ) protein deposition 35 Endothelial cells, LP-BM5 murine leukaemia virus infection 287 Energy metabolism down-regulated oxidative phosphorylation in Alzheimer’s disease 473 oxidative stress/neuronal degeneration in Alzheimer’s disease 435 Enzymatic activity free radical scavenging enzymes in amyotrophic lateral sclerosis 57 α-ketoglutarate dehydrogenase in Friedrich’s ataxia/spinocerebellar ataxia type 1, 27 Erythrocytes, free radical scavenging enzymes in amyotrophic lateral sclerosis 57 Excitotoxicity, neuroprotection against NMDA-induced 153 Exon 8 cluster, presinilin 1 gene mutations 207 FAD see Familial Alzheimer’s disease Familial Alzheimer’s disease (FAD) see also Alzheimer’s disease presenilin 1 cleavage products 293 gene mutations 207 mRNA expression 213 sporadic: clinical features 393 Fetal hippocampal neuronal cultures, maltol neurotoxicity 325 Focal cerebral ischaemia chlormethiazole-induced oedema in middle cerebral artery-occluded rat brains 81 middle cerebral artery occlusion: functional impairment 275 recombinant neutrophil inhibitory factor neuroprotection 319 Food additives, maltol neurotoxicology 325 Fornix, hippocampus neurochemical modulation in memory/learning 467 Free radicals, scavenging enzymes in amyotrophic lateral sclerosis 57 Friedrich’s ataxia, α-ketoglutarate dehydrogenase complex levels 27 Functional impairment, middle cerebral artery occlusion in marmosets 275 G-proteins acetylcholine muscarinic receptor stimulated binding in Alzheimer’s disease postmortem brain 19 Alzheimer’s disease: signal transduction 485 Gangliosides, Creutzfeld-Jacob disease 331 GAP 43, dexfenfluramine neurotoxicity in rats 145 GBR12909, striatal dopamine levels 129 GDNF see Glial cell line-derived neurotrophic factor Gene expression beta amyloid precursor protein mRNAs in Alzheimer’s disease 409 RNA synthesis inhibition/neurone survival after injury at birth (rat) 65 Genetics p53 gene knockout mice resist MPTP neurotoxicity 233 presenilin 1 gene 207, 213 prion disease strain variation evidence for independent genome 219 GFAP see Glial fibrillary acidic protein Glial cell line-derived neurotrophic factor (GDNF), review article 197 Glial cells, neurotrophic factors/Alzheimer’s disease 489 Glial fibrillary acidic protein (GFAP), dexfenfluramine neurotoxicity in rats 145 Glutamate Alzheimer’s disease neurochemical correlation 403 pyramidal neurones modulation for Alzheimer’s treatments 461
iv Glutamine, Alzheimer’s disease 477 Glutathione peroxidase, amyotrophic lateral sclerosis Goats, spongiform encephalopathies 224
57
Hamsters, spongiform encephalopathies 225 Hemispheric swelling, chlormethiazole-induced oedema in middle cerebral artery-occluded rat brains 81 5-HIAA see 5-Hydroxy-indoleacetic acid Hippocampus learning/memory neuromodulation 467 maltol neurotoxicity in neuronal cultures 325 HIV, LP-BM5 murine leukaemia virus infection of brain capillary endothelial cells 287 Homovanillic acid, Binswanger’s disease 359 Human brain Alzheimer’s disease beta amyloid precursor protein mRNAs 409 familial: presenilin 1 expression 213 neurochemical studies 381 Human spongiform encephalopathies prion protein immunohistochemistry in Creutzfeld-Jakob disease 87 strain variation 226 Hybridization, presenilin 1 mRNA expression 213 Hydrogen peroxide, beta amyloid protein cytotoxicity 441 5-Hydroxy-indoleacetic acid (5-HIAA), Binswanger’s disease 359 5-Hydroxytryptamine dexfenfluramine neurotoxicity in rat cortex 145 pyramidal neurones modulation for Alzheimer’s treatments 461 Image analysis Creutzfeld-Jakob disease prion protein immunohistochemical staining 87 neurofibrillary damage in Alzheimer’s disease/Down’s syndrome/dementia pugilistica 259 neurofibrillary tangles in Alzheimer’s disease 251 Immuno-localisation, synthetic prion protein peptide antibodies in 87V murine scrapie 101 Immunoblotting, calcium homoeostasis in Alzheimer’s disease 169 Immunogold-silver method, ultrastructural immunolocalization in 87V murine scrapie 101 Immunohistochemistry Creutzfeld-Jakob disease prion protein 87 microwave processing of formalin-fixed tissue sections 95 MPTP-induced degeneration of midbrain dopaminergic neurons 299, 313 In situ hybridization beta amyloid precursor protein mRNAs in Alzheimer’s disease 409 presenilin 1 mRNA expression 213 Inclusion dementia, motor neurone disease 339 Inflammation Alzheimer’s disease: cellular aspects 497 appican characterization 445 ischaemia-perfusion 319 Inositol (1,4,5,)-triphosphate, receptor levels in Alzheimer’s disease 169 IP3 receptors, calcium homoeostasis in Alzheimer’s disease 169 Ischaemia focal cerebral 319 middle cerebral artery occlusion: functional impairment 275 Isoquinoline derivatives, MPTP-related nigral cell loss 265 α-Ketoglutarate dehydrogenase complex (αKDGHC), Friedrich’s ataxia/spinocerebellar ataxia type 1 27 Knockout mice, p53 gene 233 Kuru, strain variation evidence for independent genome 219 Learning, hippocampus neurochemical modulation 467
Leukaemia virus, LP-BM5 murine 287 Leukocyte common antigen, Alzheimer’s disease inflammatory response: cellular aspects 497 Locus coeruleus, DSP-4-induced monoamine depletion in rodents 241 LP-BM5 murine leukaemia virus, brain capillary endothelial cells infection 287 Macrophages, common peroneal nerve post-lesion response 73 Maltol, neurotoxicity 325 Marmosets, middle cerebral artery occlusion: functional impairment 275 Medial temporal lobe, beta amyloid protein deposition in sporadic Alzheimer’s disease/Down’s syndrome 35 Memory, hippocampus neurochemical modulation 467 Messenger RNAs beta amyloid precursor protein mRNAs in Alzheimer’s disease 409 presenilin 1 expression in familial Alzheimer’s disease 213 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine see MPTP 1-Methyl-4-phenylpyridinium see MPP+ Mice C57BL/6J mice, common peroneal nerve lesion 73 DSP-4-induced monoamine depletion 241 immuno-localisation of synthetic prion protein peptide antibodies in 87V murine scrapie 101 LP-BM5 murine leukaemia virus infection of brain capillary endothelial cells 287 maltol neurotoxicity 325 microglial reaction in MPTP-induced Parkinson’s 137 MPTP-induced degeneration of midbrain dopaminergic neurons 299, 313 p53 gene knockout giving MPTP neurotoxicity resistance 233 striatal MPP+ levels after MPTP treatment 129 Microglia Alzheimer’s disease inflammatory response: cellular aspects 497 senile plaques 13 common peroneal nerve post-lesion response 73 MPTP-induced Parkinson’s in mice 137 Microwave processing, amyloid immunostaining enhancement 95 Midbrain dopaminergic neurons, MPTP-induced degeneration 299, 313 Middle cerebral artery occlusion chlormethiazole-induced oedema 81 functional impairment 275 Mitochondria Alzheimer’s disease oxidative damage 435 down-regulated oxidative phosphorylation in Alzheimer’s disease 473 MK-401, nimodipine combined therapy 153 Monkeys ciliary ganglionic ultrastructure following preganglionic axotomy 367 middle cerebral artery occlusion: functional impairment 275 Monoamine oxidase, molecular activity in Alzheimer’s type dementia 351 Monoamines, DSP-4-induced depletion in rodents 241 Monoclonal antibodies, Down’s syndrome amyloid protein analysis 115 Motor neurone disease, inclusion dementia 339 MPP+ (1-methyl-4-phenylpyridinium) (-) deprenyl/GBR-12909 effects 129 isoquinolone derivatives 265 midbrain dopaminergic neuron degeneration 299 MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) isoquinolone derivatives 265 microglial reaction in mice 137
v midbrain dopaminergic neuron degeneration 299, 313 p53 gene knockout giving neurotoxicity resistance 233 striatal dopamine levels 129 mRNAs beta amyloid precursor protein 409 presenilin 1 expression in familial Alzheimer’s disease 213 MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) reduction, prion protein peptide cytotoxicity 1 Murine see mice Muscarinic receptors changes in 19 therapy targets 453 Mutations, presenilin 1 gene 207 Myelin basic protein, LP-BM5 murine leukaemia virus infection of brain capillary endothelial cells 287 Nerve cell loss, Alzheimer’s disease 423 Nerve lesioning, macrophage/microglial cell reaction in C57BL/6J mice 73 Neurofibrillary tangles Alzheimer’s/Down’s/dementia pugilistica 259 image analysis in Alzheimer’s disease 251 stain techniques 177 Neuronal degeneration, Alzheimer’s disease 435 Neuropathology Alzheimer’s disease neurochemical studies 381 beta amyloid protein stain techniques 177 Neuropil threads Alzheimer’s disease/Down’s syndrome/dementia pugilistica 259 stain techniques 177 Neuroprotection chlormethiazole-induced oedema in middle cerebral arteryoccluded rat brains 81 (-) deprenyl against aluminium 161 middle cerebral artery occlusion 275 nimodipine/MK-801 153 recombinant neutrophil inhibitory factor 319 Neurotoxicity beta amyloid protein 441 (-) deprenyl protection 129, 161 dexfenfluramine 145 DSP-4: species differences 241 isoquinoline derivatives 265 maltol in neuroblastoma cell lines/primary murine fetal hippocampal neuronal cultures 325 MPP+/MPTP 129 MPTP resistance in p53 gene knockout mice 233 MPTP-induced midbrain degeneration 299, 313 Neurotransmitters Alzheimer’s disease 381, 403, 477, 483 DSP-4-induced monoamine depletion 241 Neurotrophic factors glial cell line-derived 197, 491 RNA synthesis inhibition/neurone survival after injury at birth (rat) 65 Neutrophils, transient focal ischaemia in rats 319 Nicotine, MPP+/MPTP neurotoxicity 129 Nicotinic receptors, Alzheimer’s therapy targets 453 Nigral cells see substantia nigra Nimodipine, MK-801 combined therapy 153 NMDA, neuroprotection against excitotoxicity 153 Non-demented brains, amyloid β (Aβ) protein deposition 35 Non-transmissible brain amyloidosis, formalin-fixed tissue sections microwave processing 95 Norepinephrine, DSP-4-induced depletion in rodents 241 Normal elderly brains, amyloid β (Aβ) protein deposition 35
Oedema, chlormethiazole-induced in middle cerebral arteryoccluded rat brains 81 Olfactory centres, Alzheimer’s disease spread 429 Olivopontocerebellar atrophy, α-ketoglutarate dehydrogenase complex levels 27 Oxidation beta amyloid protein cytotoxicity 441 damage in Alzheimer’s disease 435 phosphorylation in Alzheimer’s disease 473 P53 gene, MPTP neurotoxicity resistance in transgenic mice 233 Parkinson’s disease DSP-4-induced monoamine depletion 241 glial cell line-derived neurotrophic factor 197 isoquinoline derivatives 265 monoamine oxidase molecular activity 351 MPTP neurotoxicity resistance in transgenic mice 233 MPTP-induced degeneration of midbrain dopaminergic neurons 299, 313 MPTP-induced mice model microglial reaction 137 MPTP-induced striatal dopamine increase 129 neurofibrillary damage image analysis 259 substantia nigra pars reticulata neurons 49 synaptic plasticity 121 Pars reticulata, Parkinson’s disease 49 Parvalbumin, substantia nigra pars reticulata neurons in Parkinson’s disease 49 Pathology see Neuropathology Pathways, Alzheimer’s disease spread 429 Peripheral nervous system, ganglioside alterations in CreutzfeldJacob patients 331 Phagocytosis, Alzheimer’s disease 497 Pharmacotherapy, Alzheimer’s disease neurochemical studies 381 Phospholipase C, Alzheimer’s disease: signal transduction 483 Pick’s disease, inclusion dementia 339 Plaques Aβ40/microglia role in formation 13 associated cytokines: amyloidogenesis in Alzheimer’s disease 491 Down’s syndrome 115 stain techniques 177 Plasticity, Parkinson’s disease synapses 121 Platelet monamine oxidase, molecular activity in Alzheimer’s type dementia 351 Positron emission tomography (PET), down-regulated oxidative phosphorylation in Alzheimer’s disease 473 Postsynaptic densities, Parkinson’s disease 21 Preganglionic axotomy, ciliary ganglionic ultrastructure 367 Presenilins cleavage products 293 mRNA expression in familial Alzheimer’s disease 213 mutations in familial Alzheimer’s disease 207 processing in neuronal cell lines 293 Primary cultures (-) deprenyl neuroprotection against aluminium 161 maltol neurotoxicity 325 Primates ciliary ganglionic ultrastructure following preganglionic axotomy 367 hippocampus neurochemical modulation 467 middle cerebral artery occlusion: functional impairment 275 Prion protein immuno-localisation in 87V murine scrapie 101 immunohistochemistry in Creutzfeld-Jakob disease 87 peptide PrP106–126 cytotoxicity 1 strain variation evidence for independent genome 219 Protein kinase C, Alzheimer’s disease: signal transduction 483 Proteoglycans, appican characterization 445 Proteolysis, presenilin-l processing in neuronal cell lines 293 PrP106–126, cytotoxicity mechanism 1
vi Pyramidal cells acetylcholine receptor targets cellular localization loss 423 modulation 461 neurochemical correlates 403
453
Quantification Alzheimer’s disease structural correlates of cognition 417 neurofibrillary lesions 251, 259 prion protein immunohistochemistry in Creutzfeld-Jakob disease 87 Radioligand binding, calcium homoeostasis in Alzheimer’s disease 169 Rats chlormethiazole-induced oedema in middle cerebral artery-occluded brains 81 dexfenfluramine cortical neurotoxicity 145 DSP-4-induced monoamine depletion 241 neuroprotection against NMDA-induced excitotoxicity 153 recombinant neutrophil inhibitory factor neuroprotection in transient focal ischaemia 319 RNA synthesis inhibition/neurone survival after injury at birth 65 Receptor targets cellular localization for Alzheimer’s treatments 453 pyramidal neurones modulation for Alzheimer’s treatments 461 Recombinant neutrophil inhibitory factor, neuroprotection in focal cerebral ischaemia 319 Regeneration, common peroneal nerve cut and crush in C57BL/6J mice 73 Reperfusion, recombinant neutrophil inhibitory factor neuroprotection in transient focal ischaemia 319 Retroviruses, LP-BM5 murine leukaemia 287 Review articles, glial cell line-derived neurotrophic factor 197 RNA synthesis, actinomycin D effects on survival/regeneration of rat motoneurones injured at birth 65 Rodents, DSP-4-induced monoamine depletion 241 SAD see Sporadic Alzheimer’s disease Scrapie immuno-localisation of synthetic prion protein peptide antibodies in 87V mice 101 strain variation evidence for independent genome 219 Senile plaques, Aβ40/microglia role in formation 13 Serotonin Alzheimer’s disease 403, 477 DSP-4-induced depletion in rodents 241 Sheep, spongiform encephalopathies 224 Signal transduction acetylcholine muscarinic receptor stimulated binding of G proteins in Alzheimer’s disease postmortem brain 19 Alzheimer’s disease 483 calcium homoeostasis in Alzheimer’s disease 169 Silver stains, beta amyloid protein 177 Somatostatin, Binswanger’s disease 359 Species differences, DSP-4-induced monoamine depletion 241 Spinocerebellar ataxia type 1, α-ketoglutarate dehydrogenase complex levels 27 Splicing regulation, amyloidogenesis in Alzheimer’s disease 491 Spongiform encephalopathies immuno-localisation of synthetic prion protein peptide antibodies in 87V mice 101
prion protein immunohistochemistry in Creutzfeld-Jakob disease 87 strain variation evidence for independent genome 219 Sporadic Alzheimer’s disease (SAD) amyloid β (Aβ) protein deposition 35 familial: clinical features 393 Stains, beta amyloid protein 177 Strain differences DSP-4-induced monoamine depletion 241 transmissible spongiform encephalopathy 219 Striatum Down’s syndrome amyloid protein analysis 115 MPP+/MPTP neurotoxicity 121 Stroke, middle cerebral artery occlusion: functional impairment 275 Subacute spongiform encephalopathy, ganglioside alterations in central/peripheral nervous system 331 Substantia nigra pars compacta isoquinoline derivatives 265 p53 gene knockout mice 233 pars reticulata, Parkinson’s disease 49 Superoxide dismutase, ALS 57 Synapses, structural correlates of cognition in Alzheimer’s disease 417 Synaptic plasticity, Parkinson’s disease 121 Synthetic prion protein peptide antibodies, immuno-localisation in 87V murine scrapie 101 T cells, LP-BM5 murine leukaemia virus infection of brain capillary endothelial cells 287 Tau, beta amyloid protein stain techniques 177 Temporal course, nimodipine/MK-801 neuroprotection 153 Temporal lobe, neurofibrillary damage image analysis 259 1, 2, 3, 4,-tetrahydroisoquinoline, Parkinson’s disease 265 Thioflavin S, beta amyloid protein stain techniques 77 Thyroid hormone, amyloidogenesis in Alzheimer’s disease 489 Toxicity see Neurotoxicity Transgenic animals p53 gene knockout mice giving MPTP neurotoxicity resistance 233 spongiform encephalopathies 227 Transmissible brain amyloidosis, microwave processing of formalin-fixed tissue sections 95 Transmissible spongiform encephalopathies immuno-localisation of synthetic prion protein peptide antibodies in 87V mice 101 strain variation evidence for independent genome 219 Transmitters see Neurotransmitters Treatments, Alzheimer’s disease 507, 513 Tyrosine hydroxylase, MPTP-induced degeneration of midbrain dopaminergic neurons 299 Ubiquitin, motor neurone disease/inclusion dementia 339 Ultrastructure Alzheimer’s disease structural correlates of cognition 417 ciliary ganglionic following preganglionic axotomy 367 immuno-localisation of synthetic prion protein peptide antibodies in 87V murine scrapie 101 Viruses, LP-BM5 murine leukaemia 287 Volkensin, acetylcholine receptor targets cellular localization for Alzheimer’s therapies 453
Index to Volume 5 Author Index Agid, Y. 121 Alessandrì, M.G. 241 Altomare, C. 265 Anglade, P. 121 Araujo, D.M. 197 Armstrong, R.A. 35 Asami-Odaka, A. 13 Bailey, S.J. 319 Baker, H.F. 219, 467 Bakker, R. 153 Barton, A.J.L. 213, 293 Bassi, L. 241 Baxter, H.C. 1 Benjamin, R. 43 Bennett, J.P. Jr 233 Bettendorf, L. 27 Bjertness, E. 43 Boccardi, B. 351 Bogdanovich, N. 169 Bongioanni, P. 351 Borgna, M. 351 Brady, D.R. 473 Bratosiewicz, J. 95 Bresciani, L.G. 293 Brown, F. 213 Brown, P. 95 Brown, R.H. Jr 57 Bruce, M.E. 101 Cairns, N.J. 35 Caivano, M. 293 Campbell, C.A. 319 Candy, J.M. 43 Carotti, A. 265 Carrupt, P-A. 265 Cartwright, H. 177 Cartwright, H.R. 49 Castagna, M. 351 Cavalletti, M. 129 Cellamare, S. 265 Chandrasekaran, K. 473 Chessell, I.P. 453 Chong, A. 1 Clark, R.F. 213 Clowry, G.J. 65 Cohen, D.L. 497 Collins, F. 197 Collins, P. 145 Corsini, G.U. 129, 241 Cowburn, R.F. 19, 169, 483 Cramer, H. 359 Crook, B.W. 213 Crook, R. 207 Cross, A.J. 81 Croxton, R. 207 Cullen, K.M. 177 Cutler, N.R. 511 Czl-onkowska, A. 137 Czl-onkowski, A. 137 Davis, J.B. 293, 441 DeKosky, S.T. 417 Dewar, D. 213 Donaldson, D.M. 57
Douma, B.R.K. 153 Duff, K. 213, 293 Edwardson, J.A. 43 Efthimiopoulos, S. 445 Fascetti, F. 129 Fornai, F. 129, 241 Fowler, C.J. 483 Fowler, N. 101 Fox, N.C. 393 Francis, P.T. 461 Freeborough, P.A. 393 Fukumoto, H. 13 Gajdusek, D.C. 95 Garlind, A. 169 Garruto, R.M. 325 German, D.C. 299, 313 Goate, A.M. 213 Goodsir, C.M. 101 Graham, D.I. 213 Grauer, M.T. 359 Gray, C.W. 293 Green, A.R. 81 Halliday, G.M. 49, 177 Haltia, T. 207 Hamann, G.F. 359 Hamilton, T.C. 319 Harder, J.A. 467 Hardman, C.D. 49 Hardy, J. 207, 213, 293 Harrison, P.J. 409 Harvey, R.J. 393 Hatanpää, K. 473 Haug, L.S. 169 He, B.P. 73 Heffernan, J.M. 409 Hilt, D. 197 Hindmarsh, J.G. 145 Hironishi, M. 325 Hirsch, E.C. 121 Hirsch, O. 57 Hope, J. 1, 101 Hope, T. 399 Hunt, S. 145 Hutton, M. 207, 213, 293 Ince, P.G. 43 Ironside, J.W. 87 Iwatsubo, T. 13, 115 Jackson, M. 339 Jeffrey, M. 101 Jen, A. 489 Jenner, P 145, 265 Jiao, S. 197 Jung, A.B. 233 Kalaria, R.N. 497 Karran, E.H. 207, 213, 293 Keene, J. 399 Kelly, S.M. 1 Kilborn, J.R. 511 King, P.D. 319 Kish, S.J. 27 Kloszewska, I. 95
Kohutnicka, M. 137 Kordek, R. 95, 325 Kril, J.J. 177 Kurkowska-Jastrze,bska, I.
137
Lakshmana, M.K. 161 LaMarche, J. 27 Lancaster, S. 207 Lange, D. 57 Lantos, P.L. 35 Lapchak, P.A. 197 Leake, A. 43 Lennox, G. 339 Leong, S.K. 73 Liang, C-L. 299, 313 Liberski, P.P. 95 Lindsay, G. 27 Lowe, J. 339 Luiten, P.G.M. 153 McArthur, F.K. 43 McBride, P.A. 101 MacDonald, S.T. 87 Mackay, K.B. 319 McKenna-Yasek, D. 57 McKenzie, J.E. 251, 259 McNaught, K.St.P. 265 McRitchie, D.A. 49 Makino, M. 287 Mann, D.M.A. 115, 213, 423 Marsden, C.D. 265 Marshall, J.W.B. 275 Mastrogiacomo, F. 27 Miller P.J. 197 Miura, S. 331 Mondino, C. 351 Morris, C.M. 43 Morris, J.G.L. 49 Mouatt-Prigent, Annick 121 Munirathinam, S. 161 Murphy, P.L. 57 Murphy, V.F. 293 Myers, D. 35 Naini, A.B. 57 Nelson, E.L. 299 Nitsch, R.M. 477 Nyakas, C. 153 Ohnuki, Y. 331 Ohtani, Y. 331 Okada, Y. 287 O’Neill, C. 483 Østwald, A.C. 169 Palmer, A.M. 381 Pangalos, M.N. 445 Patel, A.J. 491 Patel, S. 319 Pearson, R.C.A. 213, 409, 429 Perez-Tur, J. 207 Phillips, H. 207 Premkumar, D.R.D. 497 Price, N.C. 1 Procter, A.W. 399 Przedborski, S. 57 Raju, T.R.
161
Rapoport, S.I. 473 Ravid, R. 19 Ridley, R.M. 219, 275, 467 Robakis, N.K. 445 Roberts, G.W. 207, 213, 251, 259, 293 Robitaille, Y. 27 Rohan de Silva, H.A. 489 Rose, S. 145 Rossor, M.N. 35, 393 Royston, M.C. 251, 259 Sanders, M.W. 409 Sato, A. 287 Scalori, V. 241 Scheff, S.W. 417 Schimrigk, K. 359 Schut, L. 27 Sen, P. 65 Shearman, M.S. 1 Shioi, J. 445 Sims, N.R. 435 Sinton, C.M. 299, 313 Smith, C.U.M. 35 Smith, T.S. 233 Sonsalla, P.K. 299, 313 Speciale, S.G. 299 Sramek, J.J. 511 Strittmatter, M. 359 Stuiver, B.T. 153 Styren, S.D. 417 Sutherland, K. 87 Suzuki, N. 13 Sydserff, S.G. 81 Tabira, T. 287 Tamai, Y. 331 Tan, C.K. 367 Tanaka, M. 287 Tay, S.S.W. 73 Tedeschi, D. 129 Testa, B. 265 Thull, U. 265 Torracca, M.T. 241 Torvik, A. 43 Trimmer, P.A. 233 Vaglini, F. 129 Vrbová, G. 65 Walaas, S.I. 169 Ward, R.V. 293 Wickenden, C. 489 Wiehager, B. 19 Wighton-Benn, W.H. 409 Wilcock, G.K. 505 Winblad, B. 19, 169 Wong, W.C. 367 Wright, K. 207 Wu, A. 445 Yanagihara, R. 95, 325 Zehr, C. 207 Zhang, Y.L. 367
ii Subject Index Acetylcholine Alzheimer’s disease neurochemical pathology 403, 461, 477, 489 hippocampus neurochemical modulation 467 muscarinic receptors: Alzheimer’s disease changes 19 pyramidal neurones modulation for Alzheimer’s treatments 461 Actinomycin D, RNA synthesis inhibition/neurone survival 65 Adenylyl cyclase, signal transduction 483 AIDS, LP-BM5 murine leukaemia virus infection of brain capillary endothelial cells 287 Aluminium, (-)deprenyl protection 161 Alz-50, neurofibrillary damage 251, 259 Alzheimer’s disease (-)deprenyl protection against aluminium 161 Aβ40 and microglia 13 acetylcholine muscarinic receptor changes 19 acetylcholine receptor targets on cortical pyramidal neurones 453 amyloid β (Aβ) protein deposition 35 apolipoprotein E 43 appican characterization 445 beta amyloid protein stain techniques 177 calcium homeostasis 169 cognitive function 473 cortical connections 429 dementia: biochemistry/clinical aspects 399 energy metabolism 435, 473 familial, sporadic 393 glial cell-derived neurotrophic factors 489 inflammatory response: cellular aspects 497 monoamine oxidase molecular activity 351 neurofibrillary tangles image analysis 251, 259 neuronal degeneration 435 neurotransmitters 381, 403, 477, 483 oxidative phosphorylation down-regulation 473 oxidative stress 435 presenilin 1, 207, 213, 293 prion protein peptide cytotoxicity 1 pyramidal neurones 423, 461 signal transduction 393 somatostatin 359 sporadic 35, 393 synapse change 417 treatments 505, 511 Amyloid protein Alzheimer’s disease/Down’s syndrome comparison 35 Down’s syndrome 35, 115 genesis 491 immuno-localisation of synthetic prion protein peptide antibodies in 87V murine scrapie 101 microwave processing of formalin-fixed tissue sections 95 senile plaques 13 stain techniques 177 Amyotrophic lateral sclerosis blood free radical scavenging enzymes 57 inclusion dementia 339 neurofibrillary lesions quantification 251 Antigen presenting cells, LP-BM5 murine leukaemia virus infection of brain capillary endothelial cells 287 Apo E see apolipoprotein E Apolipoprotein E (Apo E), Alzheimer’s disease 43 Apoptosis maltol neurotoxicology 325 RNA synthesis inhibition/neurone survival after injury at birth (rat) 65 Appican, characterization 445 Automated image analysis, neurofibrillary tangles in Alzheimer’s disease 251
Axotomies ciliary ganglionic ultrastructure following preganglionic axotomy 367 RNA synthesis inhibition/neurone survival 65 Behavioural problems, dementia: biochemistry/clinical aspects 399 Beta amyloid precursor protein appican characterization 445 cytotoxicity mechanism of prion protein peptide 1 inflammatory response cellular aspects 499 mRNAs 409 neurotrophic factors 489 signal transduction 483 Beta amyloid protein, cytotoxicity oxidative mechanisms 441 Binswanger’s disease, somatostatin 359 Blood, free radical scavenging enzymes in amyotrophic lateral sclerosis 57 Bovine spongiform encephalopathy (BSE), strain variation 226 Bowen, Professor David M.: tribute 379 Brain capillary endothelial cells, LP-BM5 murine leukaemia virus infection 287 Bridging treatments 513 C57BL/6J mice, common peroneal nerve lesion, macrophage/ microglial cell reaction 73 Calbindin-D28k, MPTP-induced degeneration of midbrain dopaminergic neurons 313 Calcium antagonists neuroprotection against NMDA-induced excitotoxicity 153 homoeostasis in Alzheimer’s disease 169 parvalbumin-containing neurons in substantia nigra pars reticulata in Parkinson’s disease 49 Calpain, Alzheimer’s disease 169 Capillary endothelial cells, LP-BM5 murine leukaemia virus infection 287 Catalase, amyotrophic lateral sclerosis 57 Cats, ciliary ganglionic ultrastructure following preganglionic axotomy 367 Caudate nucleus, Parkinson’s disease synaptic plasticity 121 Cells death see Apoptosis inflammatory response in Alzheimer’s disease 497 receptor targets for Alzheimer’s treatments 453 Cerebellum Down’s syndrome amyloid protein analysis 115 α-ketoglutarate dehydrogenase complex levels in Friedrich’s ataxia/spinocerebellar ataxia type 1 27 Cerebral cortex (-) deprenyl neuroprotection 161 Alzheimer’s disease pathways of spread 429 dexfenfluramine neurotoxicity in rats 145 IP3 receptors in Alzheimer’s disease 169 neurofibrillary tangles automated image analysis 251 pyramidal neurones: acetylcholine receptor targets cellular localization for Alzheimer’s therapies 453 Cerebrospinal fluid, somatostatin-like immunoreactivity in Binswanger’s disease 359 Chlormethiazole, oedema in middle cerebral artery-occluded rat brain 81 N-(-2-Chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4), monoamine depletion patterns in rodents 241 Cholinergic factors Alzheimer’s disease neurochemical pathology 403, 461, 477, 489 amyloidogenesis in Alzheimer’s disease 489 hippocampus neurochemical modulation 467 muscarinic receptors: Alzheimer’s disease changes 19
iii pyramidal neurones modulation for Alzheimer’s treatments 461 Chondroitin sulfate, appican characterization 445 Ciliary ganglia, ultrastructure following preganglionic axotomy 367 Circular dichroism, prion protein peptide cytotoxicity 1 [3H]citalopram binding, dexfenfluramine neurotoxicity in rat cortex 145 CJD see Creutzfeld-Jakob disease Clinical features Alzheimer’s disease: sporadic familial 393 Alzheimer’s disease bridging treatments 513 dementia behavioural problems 399 Cognitive function, Alzheimer’s disease 417, 473 Combined therapies, nimodipine/MK-801 153 Common peroneal nerve, macrophage/microglial cell reaction after cut and crush 73 Computer-imaging, MPTP-induced degeneration of midbrain dopaminergic neurons 299 Connections, cortical in Alzheimer’s disease 429 Cortex (-) deprenyl neuroprotection 161 connections/pathways in Alzheimer’s disease 429 dexfenfluramine neurotoxicity in rats 145 IP3 receptors in Alzheimer’s disease 169 neurofibrillary tangles automated image analysis 251 pyramidal neurones: acetylcholine receptor targets cellular localization for Alzheimer’s therapies 453 Creutzfeld-Jakob disease (CJD) ganglioside alterations in central/peripheral nervous system 331 prion protein immunohistochemistry 87 strain variation evidence for independent genome 219 Cytokines, plaque-associated 489 Cytotoxic T cells, LP-BM5 murine leukaemia virus infection of brain capillary endothelial cells 287 Cytotoxicity, prion protein peptide 1 Degeneration, ciliary ganglionic ultrastructure following preganglionic axotomy 367 Dementia Alzheimer’s disease beta amyloid precursor protein mRNAs 409 neurochemical studies 381, 403, 477, 483 structural correlates of cognition 417 behavioural problems: biochemistry/clinical aspects 399 monoamine oxidase molecular activity 351 motor neurone disease 339 pugilistica: neurofibrillary damage analysis 259 somatostatin-like immunoreactivity 359 Dendritic spines, Parkinson’s disease synaptic plasticity 121 (-) Deprenyl neuroprotection against aluminium 161 striatal MPP+ levels after MPTP treatment 129 Dexfenfluramine, neurotoxicity in rat cortex 145 Diffuse plaques, Down’s syndrome amyloid protein analysis 115 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide see MTT Dopaminergic neurons microglial reaction in MPTP-induced Parkinson’s 137 MPP+/MPTP neurotoxicity 129 MPTP neurotoxicity resistance in p53 gene knockout mice 233 MPTP-induced midbrain degeneration 299, 313 Double-labelling immunocytochemistry, MPTP-induced degeneration of midbrain dopaminergic neurons 313 Down’s syndrome amyloid protein 35, 115 neurofibrillary damage 259
DSP-4 see N-(-2-Chloroethyl)-N-ethyl-2-bromobenzylamine Elderly brains, amyloid β (Aβ) protein deposition 35 Endothelial cells, LP-BM5 murine leukaemia virus infection 287 Energy metabolism down-regulated oxidative phosphorylation in Alzheimer’s disease 473 oxidative stress/neuronal degeneration in Alzheimer’s disease 435 Enzymatic activity free radical scavenging enzymes in amyotrophic lateral sclerosis 57 α-ketoglutarate dehydrogenase in Friedrich’s ataxia/spinocerebellar ataxia type 1, 27 Erythrocytes, free radical scavenging enzymes in amyotrophic lateral sclerosis 57 Excitotoxicity, neuroprotection against NMDA-induced 153 Exon 8 cluster, presinilin 1 gene mutations 207 FAD see Familial Alzheimer’s disease Familial Alzheimer’s disease (FAD) see also Alzheimer’s disease presenilin 1 cleavage products 293 gene mutations 207 mRNA expression 213 sporadic: clinical features 393 Fetal hippocampal neuronal cultures, maltol neurotoxicity 325 Focal cerebral ischaemia chlormethiazole-induced oedema in middle cerebral artery-occluded rat brains 81 middle cerebral artery occlusion: functional impairment 275 recombinant neutrophil inhibitory factor neuroprotection 319 Food additives, maltol neurotoxicology 325 Fornix, hippocampus neurochemical modulation in memory/learning 467 Free radicals, scavenging enzymes in amyotrophic lateral sclerosis 57 Friedrich’s ataxia, α-ketoglutarate dehydrogenase complex levels 27 Functional impairment, middle cerebral artery occlusion in marmosets 275 G-proteins acetylcholine muscarinic receptor stimulated binding in Alzheimer’s disease postmortem brain 19 Alzheimer’s disease: signal transduction 485 Gangliosides, Creutzfeld-Jacob disease 331 GAP 43, dexfenfluramine neurotoxicity in rats 145 GBR12909, striatal dopamine levels 129 GDNF see Glial cell line-derived neurotrophic factor Gene expression beta amyloid precursor protein mRNAs in Alzheimer’s disease 409 RNA synthesis inhibition/neurone survival after injury at birth (rat) 65 Genetics p53 gene knockout mice resist MPTP neurotoxicity 233 presenilin 1 gene 207, 213 prion disease strain variation evidence for independent genome 219 GFAP see Glial fibrillary acidic protein Glial cell line-derived neurotrophic factor (GDNF), review article 197 Glial cells, neurotrophic factors/Alzheimer’s disease 489 Glial fibrillary acidic protein (GFAP), dexfenfluramine neurotoxicity in rats 145 Glutamate Alzheimer’s disease neurochemical correlation 403 pyramidal neurones modulation for Alzheimer’s treatments 461
iv Glutamine, Alzheimer’s disease 477 Glutathione peroxidase, amyotrophic lateral sclerosis Goats, spongiform encephalopathies 224
57
Hamsters, spongiform encephalopathies 225 Hemispheric swelling, chlormethiazole-induced oedema in middle cerebral artery-occluded rat brains 81 5-HIAA see 5-Hydroxy-indoleacetic acid Hippocampus learning/memory neuromodulation 467 maltol neurotoxicity in neuronal cultures 325 HIV, LP-BM5 murine leukaemia virus infection of brain capillary endothelial cells 287 Homovanillic acid, Binswanger’s disease 359 Human brain Alzheimer’s disease beta amyloid precursor protein mRNAs 409 familial: presenilin 1 expression 213 neurochemical studies 381 Human spongiform encephalopathies prion protein immunohistochemistry in Creutzfeld-Jakob disease 87 strain variation 226 Hybridization, presenilin 1 mRNA expression 213 Hydrogen peroxide, beta amyloid protein cytotoxicity 441 5-Hydroxy-indoleacetic acid (5-HIAA), Binswanger’s disease 359 5-Hydroxytryptamine dexfenfluramine neurotoxicity in rat cortex 145 pyramidal neurones modulation for Alzheimer’s treatments 461 Image analysis Creutzfeld-Jakob disease prion protein immunohistochemical staining 87 neurofibrillary damage in Alzheimer’s disease/Down’s syndrome/dementia pugilistica 259 neurofibrillary tangles in Alzheimer’s disease 251 Immuno-localisation, synthetic prion protein peptide antibodies in 87V murine scrapie 101 Immunoblotting, calcium homoeostasis in Alzheimer’s disease 169 Immunogold-silver method, ultrastructural immunolocalization in 87V murine scrapie 101 Immunohistochemistry Creutzfeld-Jakob disease prion protein 87 microwave processing of formalin-fixed tissue sections 95 MPTP-induced degeneration of midbrain dopaminergic neurons 299, 313 In situ hybridization beta amyloid precursor protein mRNAs in Alzheimer’s disease 409 presenilin 1 mRNA expression 213 Inclusion dementia, motor neurone disease 339 Inflammation Alzheimer’s disease: cellular aspects 497 appican characterization 445 ischaemia-perfusion 319 Inositol (1,4,5,)-triphosphate, receptor levels in Alzheimer’s disease 169 IP3 receptors, calcium homoeostasis in Alzheimer’s disease 169 Ischaemia focal cerebral 319 middle cerebral artery occlusion: functional impairment 275 Isoquinoline derivatives, MPTP-related nigral cell loss 265 α-Ketoglutarate dehydrogenase complex (αKDGHC), Friedrich’s ataxia/spinocerebellar ataxia type 1 27 Knockout mice, p53 gene 233 Kuru, strain variation evidence for independent genome 219 Learning, hippocampus neurochemical modulation 467
Leukaemia virus, LP-BM5 murine 287 Leukocyte common antigen, Alzheimer’s disease inflammatory response: cellular aspects 497 Locus coeruleus, DSP-4-induced monoamine depletion in rodents 241 LP-BM5 murine leukaemia virus, brain capillary endothelial cells infection 287 Macrophages, common peroneal nerve post-lesion response 73 Maltol, neurotoxicity 325 Marmosets, middle cerebral artery occlusion: functional impairment 275 Medial temporal lobe, beta amyloid protein deposition in sporadic Alzheimer’s disease/Down’s syndrome 35 Memory, hippocampus neurochemical modulation 467 Messenger RNAs beta amyloid precursor protein mRNAs in Alzheimer’s disease 409 presenilin 1 expression in familial Alzheimer’s disease 213 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine see MPTP 1-Methyl-4-phenylpyridinium see MPP+ Mice C57BL/6J mice, common peroneal nerve lesion 73 DSP-4-induced monoamine depletion 241 immuno-localisation of synthetic prion protein peptide antibodies in 87V murine scrapie 101 LP-BM5 murine leukaemia virus infection of brain capillary endothelial cells 287 maltol neurotoxicity 325 microglial reaction in MPTP-induced Parkinson’s 137 MPTP-induced degeneration of midbrain dopaminergic neurons 299, 313 p53 gene knockout giving MPTP neurotoxicity resistance 233 striatal MPP+ levels after MPTP treatment 129 Microglia Alzheimer’s disease inflammatory response: cellular aspects 497 senile plaques 13 common peroneal nerve post-lesion response 73 MPTP-induced Parkinson’s in mice 137 Microwave processing, amyloid immunostaining enhancement 95 Midbrain dopaminergic neurons, MPTP-induced degeneration 299, 313 Middle cerebral artery occlusion chlormethiazole-induced oedema 81 functional impairment 275 Mitochondria Alzheimer’s disease oxidative damage 435 down-regulated oxidative phosphorylation in Alzheimer’s disease 473 MK-401, nimodipine combined therapy 153 Monkeys ciliary ganglionic ultrastructure following preganglionic axotomy 367 middle cerebral artery occlusion: functional impairment 275 Monoamine oxidase, molecular activity in Alzheimer’s type dementia 351 Monoamines, DSP-4-induced depletion in rodents 241 Monoclonal antibodies, Down’s syndrome amyloid protein analysis 115 Motor neurone disease, inclusion dementia 339 MPP+ (1-methyl-4-phenylpyridinium) (-) deprenyl/GBR-12909 effects 129 isoquinolone derivatives 265 midbrain dopaminergic neuron degeneration 299 MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) isoquinolone derivatives 265 microglial reaction in mice 137
v midbrain dopaminergic neuron degeneration 299, 313 p53 gene knockout giving neurotoxicity resistance 233 striatal dopamine levels 129 mRNAs beta amyloid precursor protein 409 presenilin 1 expression in familial Alzheimer’s disease 213 MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) reduction, prion protein peptide cytotoxicity 1 Murine see mice Muscarinic receptors changes in 19 therapy targets 453 Mutations, presenilin 1 gene 207 Myelin basic protein, LP-BM5 murine leukaemia virus infection of brain capillary endothelial cells 287 Nerve cell loss, Alzheimer’s disease 423 Nerve lesioning, macrophage/microglial cell reaction in C57BL/6J mice 73 Neurofibrillary tangles Alzheimer’s/Down’s/dementia pugilistica 259 image analysis in Alzheimer’s disease 251 stain techniques 177 Neuronal degeneration, Alzheimer’s disease 435 Neuropathology Alzheimer’s disease neurochemical studies 381 beta amyloid protein stain techniques 177 Neuropil threads Alzheimer’s disease/Down’s syndrome/dementia pugilistica 259 stain techniques 177 Neuroprotection chlormethiazole-induced oedema in middle cerebral arteryoccluded rat brains 81 (-) deprenyl against aluminium 161 middle cerebral artery occlusion 275 nimodipine/MK-801 153 recombinant neutrophil inhibitory factor 319 Neurotoxicity beta amyloid protein 441 (-) deprenyl protection 129, 161 dexfenfluramine 145 DSP-4: species differences 241 isoquinoline derivatives 265 maltol in neuroblastoma cell lines/primary murine fetal hippocampal neuronal cultures 325 MPP+/MPTP 129 MPTP resistance in p53 gene knockout mice 233 MPTP-induced midbrain degeneration 299, 313 Neurotransmitters Alzheimer’s disease 381, 403, 477, 483 DSP-4-induced monoamine depletion 241 Neurotrophic factors glial cell line-derived 197, 491 RNA synthesis inhibition/neurone survival after injury at birth (rat) 65 Neutrophils, transient focal ischaemia in rats 319 Nicotine, MPP+/MPTP neurotoxicity 129 Nicotinic receptors, Alzheimer’s therapy targets 453 Nigral cells see substantia nigra Nimodipine, MK-801 combined therapy 153 NMDA, neuroprotection against excitotoxicity 153 Non-demented brains, amyloid β (Aβ) protein deposition 35 Non-transmissible brain amyloidosis, formalin-fixed tissue sections microwave processing 95 Norepinephrine, DSP-4-induced depletion in rodents 241 Normal elderly brains, amyloid β (Aβ) protein deposition 35
Oedema, chlormethiazole-induced in middle cerebral arteryoccluded rat brains 81 Olfactory centres, Alzheimer’s disease spread 429 Olivopontocerebellar atrophy, α-ketoglutarate dehydrogenase complex levels 27 Oxidation beta amyloid protein cytotoxicity 441 damage in Alzheimer’s disease 435 phosphorylation in Alzheimer’s disease 473 P53 gene, MPTP neurotoxicity resistance in transgenic mice 233 Parkinson’s disease DSP-4-induced monoamine depletion 241 glial cell line-derived neurotrophic factor 197 isoquinoline derivatives 265 monoamine oxidase molecular activity 351 MPTP neurotoxicity resistance in transgenic mice 233 MPTP-induced degeneration of midbrain dopaminergic neurons 299, 313 MPTP-induced mice model microglial reaction 137 MPTP-induced striatal dopamine increase 129 neurofibrillary damage image analysis 259 substantia nigra pars reticulata neurons 49 synaptic plasticity 121 Pars reticulata, Parkinson’s disease 49 Parvalbumin, substantia nigra pars reticulata neurons in Parkinson’s disease 49 Pathology see Neuropathology Pathways, Alzheimer’s disease spread 429 Peripheral nervous system, ganglioside alterations in CreutzfeldJacob patients 331 Phagocytosis, Alzheimer’s disease 497 Pharmacotherapy, Alzheimer’s disease neurochemical studies 381 Phospholipase C, Alzheimer’s disease: signal transduction 483 Pick’s disease, inclusion dementia 339 Plaques Aβ40/microglia role in formation 13 associated cytokines: amyloidogenesis in Alzheimer’s disease 491 Down’s syndrome 115 stain techniques 177 Plasticity, Parkinson’s disease synapses 121 Platelet monamine oxidase, molecular activity in Alzheimer’s type dementia 351 Positron emission tomography (PET), down-regulated oxidative phosphorylation in Alzheimer’s disease 473 Postsynaptic densities, Parkinson’s disease 21 Preganglionic axotomy, ciliary ganglionic ultrastructure 367 Presenilins cleavage products 293 mRNA expression in familial Alzheimer’s disease 213 mutations in familial Alzheimer’s disease 207 processing in neuronal cell lines 293 Primary cultures (-) deprenyl neuroprotection against aluminium 161 maltol neurotoxicity 325 Primates ciliary ganglionic ultrastructure following preganglionic axotomy 367 hippocampus neurochemical modulation 467 middle cerebral artery occlusion: functional impairment 275 Prion protein immuno-localisation in 87V murine scrapie 101 immunohistochemistry in Creutzfeld-Jakob disease 87 peptide PrP106–126 cytotoxicity 1 strain variation evidence for independent genome 219 Protein kinase C, Alzheimer’s disease: signal transduction 483 Proteoglycans, appican characterization 445 Proteolysis, presenilin-l processing in neuronal cell lines 293 PrP106–126, cytotoxicity mechanism 1
vi Pyramidal cells acetylcholine receptor targets cellular localization loss 423 modulation 461 neurochemical correlates 403
453
Quantification Alzheimer’s disease structural correlates of cognition 417 neurofibrillary lesions 251, 259 prion protein immunohistochemistry in Creutzfeld-Jakob disease 87 Radioligand binding, calcium homoeostasis in Alzheimer’s disease 169 Rats chlormethiazole-induced oedema in middle cerebral artery-occluded brains 81 dexfenfluramine cortical neurotoxicity 145 DSP-4-induced monoamine depletion 241 neuroprotection against NMDA-induced excitotoxicity 153 recombinant neutrophil inhibitory factor neuroprotection in transient focal ischaemia 319 RNA synthesis inhibition/neurone survival after injury at birth 65 Receptor targets cellular localization for Alzheimer’s treatments 453 pyramidal neurones modulation for Alzheimer’s treatments 461 Recombinant neutrophil inhibitory factor, neuroprotection in focal cerebral ischaemia 319 Regeneration, common peroneal nerve cut and crush in C57BL/6J mice 73 Reperfusion, recombinant neutrophil inhibitory factor neuroprotection in transient focal ischaemia 319 Retroviruses, LP-BM5 murine leukaemia 287 Review articles, glial cell line-derived neurotrophic factor 197 RNA synthesis, actinomycin D effects on survival/regeneration of rat motoneurones injured at birth 65 Rodents, DSP-4-induced monoamine depletion 241 SAD see Sporadic Alzheimer’s disease Scrapie immuno-localisation of synthetic prion protein peptide antibodies in 87V mice 101 strain variation evidence for independent genome 219 Senile plaques, Aβ40/microglia role in formation 13 Serotonin Alzheimer’s disease 403, 477 DSP-4-induced depletion in rodents 241 Sheep, spongiform encephalopathies 224 Signal transduction acetylcholine muscarinic receptor stimulated binding of G proteins in Alzheimer’s disease postmortem brain 19 Alzheimer’s disease 483 calcium homoeostasis in Alzheimer’s disease 169 Silver stains, beta amyloid protein 177 Somatostatin, Binswanger’s disease 359 Species differences, DSP-4-induced monoamine depletion 241 Spinocerebellar ataxia type 1, α-ketoglutarate dehydrogenase complex levels 27 Splicing regulation, amyloidogenesis in Alzheimer’s disease 491 Spongiform encephalopathies immuno-localisation of synthetic prion protein peptide antibodies in 87V mice 101
prion protein immunohistochemistry in Creutzfeld-Jakob disease 87 strain variation evidence for independent genome 219 Sporadic Alzheimer’s disease (SAD) amyloid β (Aβ) protein deposition 35 familial: clinical features 393 Stains, beta amyloid protein 177 Strain differences DSP-4-induced monoamine depletion 241 transmissible spongiform encephalopathy 219 Striatum Down’s syndrome amyloid protein analysis 115 MPP+/MPTP neurotoxicity 121 Stroke, middle cerebral artery occlusion: functional impairment 275 Subacute spongiform encephalopathy, ganglioside alterations in central/peripheral nervous system 331 Substantia nigra pars compacta isoquinoline derivatives 265 p53 gene knockout mice 233 pars reticulata, Parkinson’s disease 49 Superoxide dismutase, ALS 57 Synapses, structural correlates of cognition in Alzheimer’s disease 417 Synaptic plasticity, Parkinson’s disease 121 Synthetic prion protein peptide antibodies, immuno-localisation in 87V murine scrapie 101 T cells, LP-BM5 murine leukaemia virus infection of brain capillary endothelial cells 287 Tau, beta amyloid protein stain techniques 177 Temporal course, nimodipine/MK-801 neuroprotection 153 Temporal lobe, neurofibrillary damage image analysis 259 1, 2, 3, 4,-tetrahydroisoquinoline, Parkinson’s disease 265 Thioflavin S, beta amyloid protein stain techniques 77 Thyroid hormone, amyloidogenesis in Alzheimer’s disease 489 Toxicity see Neurotoxicity Transgenic animals p53 gene knockout mice giving MPTP neurotoxicity resistance 233 spongiform encephalopathies 227 Transmissible brain amyloidosis, microwave processing of formalin-fixed tissue sections 95 Transmissible spongiform encephalopathies immuno-localisation of synthetic prion protein peptide antibodies in 87V mice 101 strain variation evidence for independent genome 219 Transmitters see Neurotransmitters Treatments, Alzheimer’s disease 507, 513 Tyrosine hydroxylase, MPTP-induced degeneration of midbrain dopaminergic neurons 299 Ubiquitin, motor neurone disease/inclusion dementia 339 Ultrastructure Alzheimer’s disease structural correlates of cognition 417 ciliary ganglionic following preganglionic axotomy 367 immuno-localisation of synthetic prion protein peptide antibodies in 87V murine scrapie 101 Viruses, LP-BM5 murine leukaemia 287 Volkensin, acetylcholine receptor targets cellular localization for Alzheimer’s therapies 453